GLP-1/amylin co-agonist

What is GLP-1/amylin co-agonist?

A next-generation co-agonist combining GLP-1 and amylin activity, with strong early-phase weight-loss signals.

This profile is educational. It organizes publicly discussed research context for GLP-1/amylin co-agonist and related naming aliases — it is not a treatment guide.

Proposed mechanism

Single molecule or co-formulation targeting both GLP-1 and amylin pathways for enhanced satiety and weight reduction.

Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.

Current research notes

Human evidence grade: Early-stage human research

Preclinical evidence grade: Moderate human evidence

Amycretin is an early-stage investigational agent from Novo Nordisk combining amylin and GLP-1 agonism. Initial trial data reported rapid and substantial weight loss, generating significant research interest. Human evidence remains early-stage with limited published peer-reviewed data; long-term safety and durability are unknown.

Key uncertainties

• Durability of weight loss
• Comparison with CagriSema and triple agonists

Research areas being studied

• Obesity
• Combination incretin therapy

Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.

Safety & side-effect notes

Reported or discussed adverse effects

• Nausea reported in early trials
• GI effects expected class effect

Additional risks & considerations

• Very limited long-term human data
• GI effects anticipated
• Early development risk

Regulatory status

Investigational

Regulatory framing here is educational and can lag policy changes. Check official sources for current status.

Frequently asked questions

References & sources

• Novo Nordisk investigators (2024). Amycretin early clinical development overview — Conference proceedings. Evidence type: human.